Finnish cancer drug expenditure surge linked to single pharmaceutical product

An investigation by Yle identifies that rising costs in Finland's wellbeing services counties are primarily driven by a single cancer medication. While the Ministry of Social Affairs and Health maintains that patient access remains secure, the shift of non-reimbursed drug costs to regional budgets highlights growing fiscal pressure on the healthcare system.